*NOTE: Enrollment is closed for this study*
The use of cannabinoid derivatives in the treatment of a variety of neurological disorders in humans has recently been explored, particularly in the treatment of chronic pain and epilepsy. Full spectrum cannabinoid rich industrial hemp-based nutraceuticals (HBN) below 0.3% THC have been shown to have no psychotropic effects and modest activity through non-cannabinoid receptor routes affecting the serotonergic, glycinergic and GABA neurotransmission pathways that may be able to diminish pain, as well as inflammation.
Some patients will receive a placebo and regular pain medication post surgery. The other patients will get the hemp-derived nutraceutical in addition to the regular pain medication.